HALO Stock UPDATES Halozyme Therapeutics (HALO) 9.31 10/29/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 29, 2014 at 11:04 PM

Halozyme Therapeutics (HALO) 9.31 $HALO

NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39), ILMN: 188.88 (-1.77), EXAS: 24.66 (-0.34)

Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 4:54PM CDT
Vertex Pharmaceuticals Inc.'s (VRTX) Kaydeco got favorable vote from PADAC for the treatment of 6 year old and above cystic fibrosis patients with R117H mutation.
MDVN: 99.55 (-1.63), VRTX: 109.91 (-4.16), HALO: 9.31 (-0.05), LGND: 53.33 (+1.44)

Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 12:10PM CDT
Biogen (BIIB) raised its earnings guidance for 2014 once again.
MDVN: 99.55 (-1.63), BIIB: 315.06 (-2.97), HALO: 9.31 (-0.05), LGND: 53.33 (+1.44)

Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 99.55 (-1.63), HALO: 9.31 (-0.05), LGND: 53.33 (+1.44)

Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 99.55 (-1.63), OREX: 4.06 (-0.13), HALO: 9.31 (-0.05), LGND: 53.33 (+1.44)

Illumina (ILMN) Looks Strong: Stock Gains 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 7:44AM CDT
Illumina (ILMN) was a big mover last session, as the company saw its shares jump over 9% on the day
MACK: 9.19 (-0.16), MDVN: 99.55 (-1.63), HALO: 9.31 (-0.05), ILMN: 188.88 (-1.77)

NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 99.55 (-1.63), HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39)

Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 9.19 (-0.16), MDVN: 99.55 (-1.63), HALO: 9.31 (-0.05), ILMN: 188.88 (-1.77)

Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 9.19 (-0.16), HALO: 9.31 (-0.05), VTL: 17.89 (-0.39), ILMN: 188.88 (-1.77)

NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose over 7% on the day.
MACK: 9.19 (-0.16), HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39), ILMN: 188.88 (-1.77)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.31 (-0.05), EBS: 21.91 (-0.03), SNY: 45.22 (-2.85), FOLD: 5.52 (+0.02)

Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency
M2 - Mon Oct 20, 10:35AM CDT
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced the launch and first shipments of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI) in the United States. The treatment was approved by the U.S. Food and Drug Administration (FDA) in September of this year.
HALO: 9.31 (-0.05), BAX: 70.41 (+0.09)

Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 8:39AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) was a big mover last session, as its shares rose nearly 9% on the day.
MACK: 9.19 (-0.16), HALO: 9.31 (-0.05), EXAS: 24.66 (-0.34), REGN: 387.70 (-10.19)

Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 9.19 (-0.16), HALO: 9.31 (-0.05), EBS: 21.91 (-0.03), EXAS: 24.66 (-0.34)

Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant
PR Newswire - Mon Oct 20, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex® recombinant (hyaluronidase human injection). The FDA approved the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the Patheon® facility in Greenville, North Carolina, for production of finished Hylenex product.
HALO: 9.31 (-0.05)

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.31 (-0.05), EBS: 21.91 (-0.03), RARE: 49.90 (-0.10), LGND: 53.33 (+1.44)

Novavax (NVAX) Moves Up: Stock Adds 10.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:39AM CDT
Novavax, Inc. (NVAX) was a big mover last session, as its shares rose a little over 10% on the day.
MACK: 9.19 (-0.16), MYGN: 38.00 (+0.18), HALO: 9.31 (-0.05), NVAX: 5.41 (-0.07)

What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.31 (-0.05), EBS: 21.91 (-0.03), ENZ: 5.11 (-0.02), EPZM: 26.23 (-1.77)

Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:51AM CDT
Lexicon Pharmaceuticals, Inc. (LXRX) was a big mover last session, as its shares rose over 16% on the day.
MACK: 9.19 (-0.16), MYGN: 38.00 (+0.18), HALO: 9.31 (-0.05), LXRX: 1.43 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Heafner Takes Helm at HGTC Amid Strategic Shifts

A New Era for HGTC with Dr. Heafner at the Wheel Out of the frying pan and into the fire—Dr. Lori Heafner is stepping up to lead Horry-Georgetown Technical College (HGTC) with a clean slate and a hefty load of responsibility come January 2027. After enduring an intense national search by the Area Commission, she beat out tough competition to earn the role. It's not just...

Debt Crisis Looms: Social Security at Risk

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

Bascom's Strategic Play on a Dallas Apartment Deal

Unpacking Bascom's Jasmine Acquisition In a market that's been more slippery than a greased pig, Bascom Group's move buying up Jasmine Apartments is capturing some eyes. Situated in North Dallas, this 370-unit complex ain't just another brick in the wall—it's Bascom's 42nd entry into Texas, reinforcing their knack for sniffing out deals others might tiptoe around,...

Arizona Voters Demand Clear Plans for 2026 Election

A Shift in Voter Expectations: Clear Actions Needed Arizona voters have spoken, and they aren't looking for the same old political song and dance anymore. They crave something meatier—action, not just words. Heading into the 2026 general election, folks in the Grand Canyon State are demanding concrete solutions and straightforward answers from those who seek to lead...

ETERC's Ele Aims to Revolutionize STEM Education for All

The AI Mentor Battleground in Education Ever found yourself wondering how public schools could step up their game without dumping money down the tech rabbit hole? ETERC’s latest push with Ele may just be a game-changer for them. We're not talking about your run-of-the-mill chatbot regurgitating facts from the internet—this is an AI tricked out for personalized...

Bellissima Bags Allure Award for Curly Hair Tool

Award-Winning Tool Headlines 2026 Beauty Scene There's a shake-up in the world of hair tools, folks. Bellissima's Diffon Supreme has snagged a 2026 Allure Best of Beauty Award for its prowess in taming the curly, wavy, and coily strands we all crave to manage. Performance Meets Innovation in Bellissima's Latest Let's not beat around the bush. The Diffon Supreme's trump...

AI Ambassadors Rethink Arbitration's Future

Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...

DAHON's Tech: Crafting Folders That Ride Like Road Bikes

The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...

Calavera NY Website Revamp: Gemstone Expansion Hits

Calavera New York's Bold Online Makeover When a jewelry brand that's all about slashing retail markups makes a move this big, it's worth a real close-up look. Calavera New York, a name buzzing in the diamond and gemstone scene, just dropped a redesigned website that’s turning more than a few heads. They’re known for cutting out the middleman, a strategy that already...

Chattanooga: A New Epicenter for Quantum Computing

Quantum Leap: Chattanooga's Bold Move So Chattanooga’s making waves again, folks. EPB just unveiled its new big shot, the IonQ Forte Enterprise quantum computer. That's right, they’ve slapped a commercial quantum computer and a networking hub together, right here in this Tennessee city. Is this a tech haven or what? Not to mention, it’s the first in America. A New...